Skip to main content
Livermore
Livermore
ZHEN

Citigroup Inc

SEC CIK
0000831001
Latest filing
Aug 3, 2026

AKRO holding history

Akero Therapeutics, Inc. in every 13F filed by Citigroup Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of AKRO by Citigroup Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−17,118−100.0%Sold outHolders
Q3 202517,118$812.8K<0.1%−29,418−63.2%ReducedHolders
Q2 202546,536$2.48M<0.1%−187,636−80.1%ReducedHolders
Q1 2025234,172$9.48M<0.1%+146,255+166.4%AddedHolders
Q4 202487,917$2.45M<0.1%+36,036+69.5%AddedHolders
Q3 202451,881$1.49M<0.1%+22,612+77.3%AddedHolders
Q2 202429,269$686.7K<0.1%−226,165−88.5%ReducedHolders
Q1 2024255,434$6.45M<0.1%+66,982+35.5%AddedHolders
Q4 2023188,452$4.40M<0.1%+91,962+95.3%AddedHolders
Q3 202396,490$4.88M<0.1%+23,955+33.0%AddedHolders
Q2 202372,535$3.39M<0.1%−60,982−45.7%ReducedHolders
Q1 2023133,517$5.11M<0.1%+50,458+60.7%AddedHolders
Q4 202283,059$4.55M<0.1%+80,860+3,677.1%AddedHolders
Q3 20222,199$75.0K<0.1%−1,878−46.1%ReducedHolders
Q2 20224,077$39.0K<0.1%−8,742−68.2%ReducedHolders
Q1 202212,819$182.0K<0.1%−37,025−74.3%ReducedHolders
Q4 202149,844$1.05M<0.1%+18,563+59.3%AddedHolders
Q3 202131,281$699.0K<0.1%−44,563−58.8%ReducedHolders
Q2 202175,844$1.88M<0.1%+15,717+26.1%AddedHolders
Q1 202160,127$1.74M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.